Piramal Pharma Ltd

Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26

Please refer attached file

Company Update / General View filing →

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →

Analyst / Investor Meet - Intimation

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Company Update / Analyst / Investor Meet View filing →

Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private Limited

Please find enclosed intimation of exercise of call option for acquisition of additional equity stake in Yapan Bio Private Limited

Company Update / General View filing →

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 -Resumption Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat

Please refer attachment

Company Update / General View filing →

Analyst / Investor Meet - Outcome

Please find enclosed intimation of audio recordings of the conference call held today 30th July, 2026.

Company Update / Analyst / Investor Meet View filing →

Shareholder Meeting / Postal Ballot-Outcome of AGM

Proceedings and Voting Results of the 6th Annual General Meeting of the Company

AGM/EGM / AGM View filing →

Shareholder Meeting / Postal Ballot-Scrutinizer's Report

Report of the Scrutinizer along with the voting results of the businesses transacted at the AGM

AGM/EGM / AGM View filing →

Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Grant Of Stock Options

Grant of Stock Options pursuant to Piramal Pharma Limited - Employee Stock Option and Inc entive Plan 2022

Company Update / General View filing →

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Temporary Suspension Of Operations At Company'S Facilities Located At Ahmedabad, Gujarat.

Please refer attachment.

Company Update / General View filing →

Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June, 2026.

Piramal Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....

Board Meeting / Board Meeting View filing →

Analyst / Investor Meet - Intimation

Please find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.

Company Update / Analyst / Investor Meet View filing →

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund

Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Successful closure of US FDA Inspection at Piramal Pharma's manufacturing facility located at Sellersville (USA) facility

Company Update / General View filing →

Notice Of The 6Th Annual General Meeting And Annual Report For The Financial Year 2025-26

Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26

AGM/EGM / AGM View filing →

Reg. 34 (1) Annual Report.

Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26

Others / Reg. 34 (1) Annual Report View filing →

Business Responsibility and Sustainability Reporting (BRSR)

Business Responsibility and Sustainability Reporting for the Financial Year 2025-26

Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

Closure of Trading Window

Please refer attached file

Insider Trading / SAST / Closure of Trading Window View filing →

Clarification sought from Piramal Pharma Ltd

The Exchange has sought clarification from Piramal Pharma Ltd on June 23, 2026, with reference to news appeared in https://www.ndtvprofit.com dated June 23, 2026, quoting "Piramal Pharma ....

Company Update / Clarification

Clarification On News Item Appearing On NDTV Profit Captioned - "Piramal Pharma Share Price Spikes Over 10% - What Is Driving The Rally?"

Please refer attached file

Company Update / General View filing →

Newspaper Publication

Newspaper Advertisement for information regarding 6th Annual General Meeting of the Company

Company Update / Newspaper Publication View filing →

Allotment of ESOP / ESPS

Please find enclosed intimation of allotment of ESOPs.

Company Update / Allotment of ESOP / ESPS View filing →

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Permanent revocation of closure directions for Company's Dahej Site

Company Update / General View filing →